Congratulations to Helen McCarthy, Darach Neeson, and the rest of the pHion Therapeutics team, as well as Ben Toogood at invoX Pharma Limited. We look forward to continuing to support the company, along with QUBIS Ltd and other investors, on its exciting growth journey.
Article taken from: https://finance.yahoo.com/
pHion is developing a pipeline of therapeutic and prophylactic vaccines focussed on oncology and infectious diseases. The company’s proprietary RALA platform can deliver anionic molecules such as mRNA and saRNA in a stealth-like way, evading detection, to generate a potent antigen-specific CD8+ T-cell response. The RALA peptide-based drug delivery system is based on a sequence of 30 amino acids which condenses anionic cargo, irrespective of size, into nanoparticles that are highly efficient at cellular entry and can outperform currently available technologies. Compared with traditional mRNA vaccine delivery platforms, the RALA platform has the added advantage of ease of scalability and logistics, including stability at room temperature.
Under the leadership of CEO and Founder, Prof Helen McCarthy, pHion has made significant progress since invoX’s initial investment in June 2021, with advances made across all pre-clinical programs and the establishment of a laboratory in Belfast, Northern Ireland for the production of pHion’s mRNA vaccines. The additional investment will support growth of the company’s proprietary RALA platform with an immediate focus on the advancement of pHion’s lead project, PTX_V1, into clinical trials in the first half of 2024. PTX_V1 is a first-in-class therapeutic vaccine for the treatment of human papilloma virus (HPV)-related cancers. Infection with HPV is responsible for approximately 90% of cervical cancers and up to 70% of oropharyngeal cancers, with a high unmet clinical need. pHion’s pipeline also includes differentiated therapeutic vaccines for the treatment of ovarian (PTX_V5) and prostate (PTX_V3) cancers.
"At pHion Therapeutics, it is our mission to pioneer next generation, first-in-class vaccines for infectious disease and oncology through stealth-like delivery of mRNA. With the additional support from invoX, we are set to accelerate our lead candidate, PTX_V1, to be ready for the clinic in 2024 and further develop our exciting preclinical pipeline of therapeutic and prophylactic mRNA vaccines. mRNA vaccines have the potential to truly transform healthcare interventions globally, and pHion will be at the forefront of this transformation, enabled by the RALA platform delivery technology."
pHion Therapeutics is a UK based vaccine development company, with a pipeline of therapeutic and prophylactic vaccines focussed on oncology and viral infections. The company’s proprietary RALA platform can deliver nucleic acids in a stealth-like way, evading detection, to generate a potent antigen-specific CD8+ T-cell response. pHion’s lead product is a therapeutic vaccine against HPV driven cancers (PTX_V1), with Phase I/IIA clinical trials planned to commence in 2024.
For further information about pHion Therapeutics, please visit: https://www.phiontx.co.uk.
invoX Pharma was incorporated in March 2021 and is a wholly owned subsidiary of Sino Biopharm, a global top 40 pharmaceutical company with more than 24,000 employees. UK-based invoX is a fully integrated biopharmaceutical company focusing on R&D and business development activities outside of China, with a core focus on oncology and respiratory therapeutics. invoX’s main goal is to become a fully integrated biopharmaceutical company with a pipeline of innovative products addressing unmet healthcare needs worldwide. At its core, the Company aspires to improve patients’ lives by creating access to innovative medicines.
For further information about invoX Pharma, please visit: https://invoxpharma.com/.